Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock [TheStreet.com]
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics (LUCD) had its price target raised by Ascendiant Capital Markets from $8.25 to $9.00. They now have a "buy" rating on the stock.
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference